Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Reply: To PMID 23258530.

Everhart JE, Wright E.

Hepatology. 2014 Mar;59(3):1214-5. doi: 10.1002/hep.26650. Epub 2014 Jan 13. No abstract available.

2.

Relating serum GGT to ALT activity enhances its predictability on treatment outcome in chronic hepatitis C.

Amanzada A, Ramadori G, Mihm S.

Hepatology. 2014 Mar;59(3):1213-4. doi: 10.1002/hep.26651. Epub 2014 Jan 13. No abstract available.

PMID:
23907789
3.

Reply: To PMID 23300053.

Schäfer A, Kraus MR, Scheurlen M.

Hepatology. 2014 Jul;60(1):431-2. No abstract available.

PMID:
25105195
4.
5.

Reply to "Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment".

Lin JA, Shih YL.

J Formos Med Assoc. 2015 Feb;114(2):197-9. doi: 10.1016/j.jfma.2014.05.006. Epub 2014 Jul 4. No abstract available.

6.

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?

Jung YK, Kim JH.

Clin Mol Hepatol. 2013 Mar;19(1):26-8. doi: 10.3350/cmh.2013.19.1.26. Epub 2013 Mar 25. No abstract available.

7.

Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.

Chung WJ.

Clin Mol Hepatol. 2012 Sep;18(3):268-71. doi: 10.3350/cmh.2012.18.3.268. Epub 2012 Sep 25. No abstract available.

8.

Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.

Hadziyannis SJ, Sevastianos V.

Aliment Pharmacol Ther. 2013 Feb;37(4):491. doi: 10.1111/apt.12175. No abstract available.

9.

Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.

Hu CC, Chien RN.

Aliment Pharmacol Ther. 2013 Feb;37(4):492. doi: 10.1111/apt.12189. No abstract available.

10.

[Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].

Dou XG.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):486-7. Chinese. No abstract available.

PMID:
19912678
11.

Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).

Everhart JE, Wright EC.

Hepatology. 2013 May;57(5):1725-33. doi: 10.1002/hep.26203. Epub 2013 Apr 5.

12.

Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.

Heo J.

Korean J Hepatol. 2011 Sep;17(3):180-2. doi: 10.3350/kjhep.2011.17.3.180. No abstract available.

13.

Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.

[No authors listed]

Ann Intern Med. 2013 Dec 3;159(11):I-14. doi: 10.7326/0003-4819-159-11-201312030-00001. No abstract available.

PMID:
24297207
14.

[Peginterferon alpha combined with ribavirin for the treatment of chronic hepatitis C].

Xu Y, Wang JB.

Zhonghua Gan Zang Bing Za Zhi. 2011 Jun;19(6):415-6. Chinese. No abstract available.

PMID:
22053369
15.

Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral.

Mishra A, Younossi Z.

Aliment Pharmacol Ther. 2013 Sep;38(5):557-8. doi: 10.1111/apt.12419. No abstract available.

16.

[Sofosbuvir: alternative in hepatitis C infection?].

Blum HE.

Dtsch Med Wochenschr. 2013 Aug;138(33):1646-7. doi: 10.1055/s-0032-1329055. Epub 2013 Aug 2. German. No abstract available.

PMID:
23913349
17.
18.

Sofosbuvir for previously untreated chronic hepatitis C infection.

Hsu CS.

N Engl J Med. 2013 Aug 15;369(7):678. doi: 10.1056/NEJMc1307641#SA1. No abstract available.

PMID:
23944317
19.

Sofosbuvir for previously untreated chronic hepatitis C infection.

Lawitz E, Gane EJ.

N Engl J Med. 2013 Aug 15;369(7):678-9. doi: 10.1056/NEJMc1307641. No abstract available.

20.

[Effect of peginterferon alpha-2a combinated with ribavirin in the treatment of rebound patient with chronic hepatitis C: a case report].

He Q, Li ZY.

Zhonghua Gan Zang Bing Za Zhi. 2010 Oct;18(10):794. doi: 10.3760/cma.j.issn.1007-3418.2010.10.019. Chinese. No abstract available.

PMID:
21059303
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk